Sophia T. Pallenberg
Carl Neuberg Str. 1
Hannover, NI 30625, Germany
Hannover, NI 30625, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Effects of elexacaftor/tezacaftor/ivacaftor on the nasal microbial metagenome in cystic fibrosis.
Journal: Microbiology spectrum
Published: July 13, 2026
Type 3 innate lymphoid cells dominate the ILC compartment in endstage lung disease.
Journal: Frontiers in immunology
Published: September 30, 2025
Cystic fibrosis transmembrane conductance regulator therapy with elexacaftor/tezacaftor/ivacaftor reduces detection of hallmark cystic fibrosis pathogens in Europe: progress made but no time to slow down.
Journal: ERJ open research
Published: February 13, 2025
Reduction of systemic inflammation by elexacaftor/tezacaftor/ivacaftor correlates with lung function improvement in cystic fibrosis.
Journal: The European respiratory journal
Published: January 23, 2025
Progress of personalized medicine of cystic fibrosis in the times of efficient CFTR modulators.
Journal: Molecular and cellular pediatrics
Published: January 20, 2025
PREFUL MRI for Monitoring Perfusion and Ventilation Changes after Elexacaftor-Tezacaftor-Ivacaftor Therapy for Cystic Fibrosis: A Feasibility Study.
Journal: Radiology. Cardiothoracic imaging
Published: April 04, 2024
Impact of elexacaftor/tezacaftor/ivacaftor therapy on lung clearance index and magnetic resonance imaging in children with cystic fibrosis and one or two F508del alleles.
Journal: The European respiratory journal
Published: January 01, 2024
The Anion Channel TMEM16a/Ano1 Modulates CFTR Activity, but Does Not Function as an Apical Anion Channel in Colonic Epithelium from Cystic Fibrosis Patients and Healthy Individuals.
Journal: International journal of molecular sciences
Published: August 14, 2023
Spirometric and anthropometric improvements in response to elexacaftor/tezacaftor/ivacaftor depending on age and lung disease severity.
Journal: Frontiers in pharmacology
Published: February 22, 2023
Differential effects of ELX/TEZ/IVA on organ-specific CFTR function in two patients with the rare CFTR splice mutations c.273+1G>A and c.165-2A>G.
Journal: Frontiers in pharmacology
Published: January 29, 2023
Changes in cystic fibrosis transmembrane conductance regulator protein expression prior to and during elexacaftor-tezacaftor-ivacaftor therapy.
Journal: Frontiers in pharmacology
Published: December 02, 2022
Impact of Elexacaftor/Tezacaftor/Ivacaftor Therapy on the Cystic Fibrosis Airway Microbial Metagenome.
Journal: Microbiology spectrum
Published: September 26, 2022
Last Updated: 09/26/2026